-+ 0.00%
-+ 0.00%
-+ 0.00%

Borui Pharmaceutical announced that in the first half of 2026, the company had no major irregularities and invested 249.37910,000 yuan in R&D, accounting for 36.78% of revenue. The company has risks such as innovative drug research and development, talent team building, performance fluctuations, product substitution, drug quality control, production safety, tax preferential policy changes, industry policy adjustments, and exchange rate fluctuations. The storage and use of funds raised by the company complies with relevant regulations, and there are no cases of illegal use.

Zhitongcaijing·09/17/2026 08:41:13
Listen to the news
Borui Pharmaceutical announced that in the first half of 2026, the company had no major irregularities and invested 249.37910,000 yuan in R&D, accounting for 36.78% of revenue. The company has risks such as innovative drug research and development, talent team building, performance fluctuations, product substitution, drug quality control, production safety, tax preferential policy changes, industry policy adjustments, and exchange rate fluctuations. The storage and use of funds raised by the company complies with relevant regulations, and there are no cases of illegal use.